Clinical DevelopmentManagement downplayed the translatability of biomarker data from an ongoing RAGE study, deciding to move to Ph2a without waiting for this data.
Financial PerformanceARWR remains engaged with FDA and potential strategic financing partners to resolve balance sheet overhang, which also drove 11/30 sell-off (-25%) and PT lowering from $60 to $50.
Treatment OutcomesPlozasiran treatment led to a rise in LDL cholesterol, which is not a desired treatment outcome even if TGs decrease.